We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.19%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$336M
AUM Growth
+$28.4M
Cap. Flow
-$47.2M
Cap. Flow %
-14.05%
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.4M
2
FLNA
Filana Therapeutics
FLNA
+$4.02M
3
VERO
Venus Concept
VERO
+$3.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.94M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.2M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$6.46M
4
BEAT
BioTelemetry, Inc.
BEAT
+$2.89M
5
BPMC
Blueprint Medicines
BPMC
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 89.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
51
DELISTED
Mersana Therapeutics
MRSN
$1.31M 0.39%
1,971
-4,140
-68% -$2.3M
BLUE
52
DELISTED
bluebird bio
BLUE
$1.31M 0.39%
2,337
– –
RCUS icon
53
Arcus Biosciences
RCUS
$3.64B
$1.29M 0.38%
49,600
-22,500
-31% -$545K
VRNA
54
DELISTED
Verona Pharma
VRNA
$1.13M 0.34%
161,507
– –
ACET icon
55
Adicet Bio
ACET
$74.7M
$1.09M 0.32%
4,849
+625
+15% +$128K
PHAS
56
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.08M 0.32%
320,542
– –
LRMR icon
57
Larimar Therapeutics
LRMR
$432M
$1.04M 0.31%
48,428
-30,727
-39% -$616K
RVMD icon
58
Revolution Medicines
RVMD
$44B
$891K 0.27%
+22,500
New +$890K
PAND
59
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$865K 0.26%
+58,222
New +$810K
MASI
60
DELISTED
Masimo
MASI
$805K 0.24%
3,000
– –
MDGL icon
61
Madrigal Pharmaceuticals
MDGL
$11.8B
$734K 0.22%
6,600
– –
NXTC icon
62
NextCure
NXTC
$23.8M
$709K 0.21%
5,417
-1,666
-24% -$215K
INGN icon
63
Inogen
INGN
$164M
$670K 0.2%
15,000
– –
LONA
64
LeonaBio Inc
LONA
$72.1M
$566K 0.17%
+1,653
New +$390K
GNFT
65
DELISTED
Genfit
GNFT
$549K 0.16%
+114,341
New +$538K
ISEE
66
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$476K 0.14%
68,951
-253,549
-79% -$1.62M
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
$393K 0.12%
22,000
– –
BEAT
68
DELISTED
BioTelemetry, Inc.
BEAT
$375K 0.11%
5,200
-55,300
-91% -$2.89M
KURA icon
69
Kura Oncology
KURA
$850M
$294K 0.09%
9,000
-30,019
-77% -$1.05M
SNDX icon
70
Syndax Pharmaceuticals
SNDX
$1.82B
$222K 0.07%
10,000
-92,713
-90% -$1.92M
SCPH
71
DELISTED
scPharmaceuticals
SCPH
$206K 0.06%
38,891
-52,009
-57% -$407K
LCTX icon
72
Lineage Cell Therapeutics
LCTX
$274M
$141K 0.04%
80,000
-15,000
-16% -$21K
AKBA icon
73
Akebia Therapeutics
AKBA
$252M
– –
-341,779
Closed -$858K
ARCT icon
74
Arcturus Therapeutics
ARCT
$211M
– –
-229,652
Closed -$9.85M
ARDX icon
75
Ardelyx
ARDX
$988M
– –
-144,650
Closed -$759K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, DAFNA Capital Management held 90 positions worth $336M, up 9.2% from $308M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $47.2M in Q4 2020, closing 16 positions and reducing 26 holdings. Its most notable exit was Immunomedics Inc, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Filana Therapeutics worth $3.07M.

  • DAFNA Capital Management's largest Q4 2020 buy was Filana Therapeutics: 450,000 shares worth $3.07M.
  • DAFNA Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2020, an estimated $4.4M increase.
  • DAFNA Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $6.46M.
  • DAFNA Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $22.2M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $336M portfolio in Q4 2020.
  • DAFNA Capital Management opened 10 new positions and closed 16 in Q4 2020.
  • DAFNA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $336M.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.